Mesoblast Limited (MESO)

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in...

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and...

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It Canada NewsWire NEW...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for...

Form 3 - Initial statement of beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in...

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial...

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue...

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients...

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW...

Form 3 - Initial statement of beneficial ownership of securities